Entrar Registro gratuito

Inhibrx Ret. no patrimônio

Qual é o Ret. no patrimônio de Inhibrx?

O Ret. no patrimônio de Inhibrx, Inc. é 1,617.60%

Qual é a definição de Ret. no patrimônio?



O retorno sobre o patrimônio é uma medida da lucratividade de um negócio em relação ao valor contábil do patrimônio líquido. É calculado pela divisão do lucro líquido do exercício pelo total do patrimônio líquido.

The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.

Ret. no patrimônio de empresas na Setor Health Care em NASDAQ em comparação com Inhibrx

O que Inhibrx faz?

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Empresas com ret. no patrimônio semelhantes a Inhibrx